Boji Medical cancels stock options after exercise period ends

Guangzhou Boji Medical & Biotechnological (SZSE:300404) announced the cancellation of 235,240 stock options after the second exercise period of its 2022 stock option incentive plan concluded. The decision, approved at the 14th meeting of the Fifth Board of Directors on June 6, 2025, reflects the fact that certain grantees did not fully exercise their allocated options within the designated timeframe. This cancellation aligns with the company’s established regulations detailed in the "2022 Stock Option Incentive Plan (Draft)" and the "2022 Stock Option Incentive Plan Implementation and Assessment Management Measures." The company stated that this action will not significantly impact the company's financial standing, operations, or management team. This action follows a series of adjustments to the 2022 stock option plan, including previous cancellations due to employee departures and modifications to exercise prices based on the company’s profit distribution.